制备禽腺病毒4型(FAdV-4)Fiber2蛋白的特异性单克隆抗体,将重组蛋白FAdV-4 Fiber2纯化后作为免疫原免疫BALB/c小鼠,分离脾脏中的淋巴细胞,与小鼠骨髓瘤细胞SP2/0进行融合,筛选得到10株能稳定分泌抗FAdV-4 Fiber2蛋白单克隆抗体的阳性杂交瘤细胞株1B5F1、1B5G11、1B5C1、1B5D2、1B5E3、1B5F3、1B5E4、1B5G4、1B5A8、1B5G8,取分泌抗体水平最高的1B5F1细胞株制备腹水,利用斑点杂交(Dot blot)和间接免疫荧光试验(IFA)进行特异性检测.结果表明,成功制备10株杂交瘤细胞株;制备的腹水能与FAdV-4 Fiber2蛋白及FAdV-4攻毒后的鸡肝组织产生特异性反应,证明成功制备了FAdV-4 Fiber2蛋白特异性单克隆抗体.

Hepatitis-hydropericardium syndrome (HHS) is widespread in China and causes high chicken mortality that results in great economic losses. A safe and effective vaccine is needed, and a subunit vaccine has potential for development. In this study, a truncated region of the FAdV-4 fiber 2 fused with coding sequence of one epitope of hexon was expressed in a prokaryotic expression system, and the immune protective effects of different doses of recombinant fiber 2 subunit vaccine on SPF chickens were compared. The recombinant fiber2 (Gly275- Pro479 aa)-hexon (Met21-Val51 aa) protein (rFH) obtained in Escherichia coli showed good solubility. The chicken survival rate at the lowest dose (2.5 mu g/bird) was 75% (6/8), and at higher doses (>5 mu g/bird) was 100% (8/8) in challenge experiment. Two chickens in the 2.5 mu g/bird treatment showed severe lesions, while birds in the higher dose treatments showed no obvious tissue damage as determined by histopathologic analysis of liver and spleen. Absolute quantitative real-time PCR showed no viral load in the >5 mu g/bird treatments, but two chickens in the 2.5 mu g/bird treatment had high viral loads. The challenge experience demonstrated that the rFH vaccine provided 100% protection at >5 mu g/bird. These results suggested that rFH protein as an effective vaccine to protect against FAdV-4 and provided a new idea for the development of vaccine against HHS.

目的 对重组猪尿酸氧化酶(recombinant porcine urate oxidase,rPUOX)进行突变改造,以增加rPUOX上可供聚乙二醇(polyethylene glycol,PEG)耦合的赖氨酸(Lys)残基数,探究PEG修饰对改造前后的酶液在SPF鸡体内的药效和抗原屏蔽作用的影响.方法 对纯化的基因改造前后的rPUOX进行PEG化修饰,修饰蛋白静脉注射SPF鸡,共4次,每次间隔7d.实验分为20×5K PEG-rPUOX-215组、20×5K PEG-rPUOX组和空白对照组(0.9％生理盐水).于鸡翼根静脉处采血,用血糖尿酸测试仪及尿酸测试条测定尿酸浓度,酶反应-紫外分光光度法检测尿酸酶活性,间接ELISA法检测免疫原性.结果 20×5K PEG-rPUOX-215和20×5K PEG-rPUOX均获得充分修饰,且前者修饰效果更好.第1、2次注射,降低鸡血尿酸幅度20×5K PEG-rPUOX-215组高于20×5K PEG-rPUOX组约11％和6％.3次注射药效维持时间20×5K PEG-rPUOX组相较于20×5K PEG-rPUOX-215组逐次降低0、24和48 h.20×5K PEG-rPUOX-215组抗体产生速率相对较慢,且14 d抗体阳性率低于20×5K PEG-rPUOX组约14.3％.结论 20×5K PEG-rPUOX-215修饰后药效学作用更显著,药物半衰期延长,且免疫原性相对较低,为研制低免疫原性的rPUOX及实现临床上多次给药提供了新的方法和思路.

为建立一种检测非洲猪瘟病毒(ASFV)抗体的间接ELISA(iELISA)方法,对构建的ASFV P30基因表达工程菌诱导表达后,将获取的重组ASFV P30蛋白进行纯化和Western-blot检测,然后以纯化的重组蛋白为抗原,建立了ASFV抗体iELISA检测方法,并进行了特异性、灵敏性、重复性试验;同时与基于ASFV P30-2His6蛋白(N、C末端各融合1个His6标签)的iELISA方法进行兽医临床样本比较试验.结果显示:重组ASFV P30蛋白和重组ASFV P30-2His6蛋白在Western-blot检测中,均能与猪ASFV阳性血清产生特异性杂交带;基于重组ASFV P30蛋白iELISA的最佳反应条件为,抗原蛋白包被质量浓度20μg/mL、血清样品稀释度1:1000、酶标二抗稀释度1:40000、血清样品检测OD450阳性结果临界值0.22.该方法仅对ASFV阳性血清呈特异性反应,1:3200稀释的阳性血清仍可检出,批内试验和批间试验变异系数均小于10％,可以消除His标签所造成的假阳性反应.本研究建立的ASFV P30 iELISA检测方法为ASFV抗体检测提供了一种有效手段.

The Cap of porcine circovirus type 2 (PCV2) can be assembled into virus like particles (VLPs) in vitro that have multiple loops located on the particle surface. This would make it a good vehicle for displaying exogenous proteins or epitopes. We derived two epitopes, epitope B (EpB, S37HIQLIYNL45) and epitope 7 (Ep7, Q196WGRL200) from Gp5 of the highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV). We replaced the core region of Loop CD (L75PPGGGSN82) and the carboxyl terminus (K222DPPL226) of PCV2 Cap, respectively, to construct a bi-epitope chimeric PCV2 Cap. Its immunogenicity and protective effects were evaluated as one PRRSV subunit vaccine. The chimeric PCV2 Cap was soluble, efficiently expressed in an Escherichia coli expression system, and could be self-assembled into chimeric virus like particles (cVLPs) with a diameter of 12-15 nm. Western blotting confirmed that the cVLPs could be specifically recognized by anti-PCV2, anti-EpB and anti-Ep7 antibodies. The cVLPs vaccine could alleviate the clinical symptoms and reduce the viral loads after HP-PRRSV challenge in 100-120 days old pigs. These data suggest that the cVLPs vaccine could provide pigs with partial protection against homologous PRRSV strains, and it provides a new design for additional PRRSV subunit vaccines.

Introduction. PCV2 is a DNA virus that exists widely in pigs and has caused great economic losses to the pig industry worldwide. In the existing commercial PCV2 enzyme-linked immunosorbent assay (ELISA) kits both natural infection with PCV2 and vaccine immunization produce results that are positive for PCV2 Cap antibodies and therefore they cannot diagnose PCV2 infection in immunized pig farms.Aim. To establish a PCV2 non-structural protein antibody detection method that distinguishes between antibodies resulting from natural prior exposure (infection) and those induced by subunit vaccine immunization.Methodology. Based on the non-structural Rep' protein, we established an indirect ELISA (iELISA) using sera from guinea pigs and piglets.Results. The results for iELISA for guinea pig serum showed that animals vaccinated with a whole-virus inactivated PCV2 vaccine had 100 % (10/10) Cap antibody positivity and 100 % (10/10) Rep' antibody positivity. Guinea pigs vaccinated with a recombinant subunit PCV2 vaccine had 100 % (10/10) Cap antibody positivity, while no (0/10) guinea pigs were Rep' antibody-positive. The combined detection results for the Rep' iELISA and a PCV2 Antibody Test kit (Commercial) showed that pigs vaccinated with a whole-virus inactivated PCV2 vaccine or PCV2 SD/2017 had 100 % (5/5) Cap antibody positivity and 100 % (5/5) Rep' antibody positivity. Pigs vaccinated with a recombinant subunit PCV2 vaccine had 100 % (5/5) Cap antibody positivity, while no (0/10) pigs were Rep' antibody-positive.Conclusion. This paper describes an effective iELISA method that can distinguish natural infection with PCV2 (Cap and Rep positive) or inoculation with a whole-virus inactivated vaccine (Cap and Rep positive) from subunit vaccine immunization (Cap-positive, Rep-negative). These comparative assays could be very useful in the control of PCV2 in pig herds.

Since 2017, novel variant strains of infectious bursal disease virus (nvIBDV) have been detected in China, while the current vaccines on the market against very virulent IBDV have limited protection against this subtype virus. In this context, a strain of the virus has been isolated, and sequencing alignment and bird regression experiments showed that the virus was IBDV, belonging to the nvIBDV subtype (and named IBDV FJ-1812). Furthermore, the Escherichia coli expression system was used to successfully express soluble nvIBDV rVP2, which is specifically recognized by an anti-IBDV standard serum and anti-nvIBDV positive serum, and could be assembled into 14 - 17 nm virus-like particles. Based on the purified nvIBDV rVP2, we developed an IBDV FJ-1812 VP2 VLP vaccine at a laboratory scale to evaluate protection by this vaccine; in addition, we also prepared an IBDV JZ 3/02 VP2 subunit vaccine targeting very virulent IBDV and evaluated its cross-protection against nvIBDV. Results of bird experiments showed that the nvIBDV rVP2 vaccine could induce high titres of specific antibodies, completely protect the bursa of Fabricius from viral infection, and provide 100% immune protection to SPF and Ross 308 broiler chickens. Furthermore, the IBDV JZ 3/02 VP2 subunit vaccine targeting very virulent IBDV could provide 60% protection for SPF chickens and 80% protection for Ross 308 broiler chickens. This report provides important technical supports for the prevention and control of nvIBDV in the future.